Immunome (IMNM) Osake Kurssi
Immunome Kurssi
Viimeisten 3 vuoden aikana Immunomen liikevaihto kasvoi 1,6 % vuodessa ja ylsi 6,94 M USD:een. Immunomen nettomarginaali −3 060,0 % on laskenut verrattuna −556,8 %:iin muutama vuosi sitten. Immunomen 12 kuukauden konsensustavoitehinta on 35,50 USD, noin yli kurssia 94,6 %. 22 analyytikosta 20 suosittaa ostoa — kokonaiskonsensus on Osta.
Immunome osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Immunome liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Immunome -osakkeesta
The business model of Immunome Inc is focused on developing targeted antibody therapies for the treatment of cancer and other diseases. The company utilizes its proprietary discovery engine, known as IMM-01, to identify novel disease-targeting antigens and generate highly specific monoclonal antibodies. These therapeutic antibodies have the potential to selectively bind to disease-related targets, thereby stimulating an immune response against cancer cells or other disease-causing agents. Through its research and development efforts, Immunome aims to advance its pipeline of antibody candidates and potentially revolutionize the treatment options available for patients.
Immunome Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Immunome Inc in the market are other companies operating in the biotechnology and pharmaceutical industries. These competitors may include companies such as Moderna Inc, BioNTech SE, Pfizer Inc, Johnson & Johnson, and Novavax Inc. Immunome Inc faces competition in the development and commercialization of novel immunotherapies and vaccines. It continuously strives to differentiate itself through its innovative pipeline, cutting-edge technology, and strong research capabilities.
Immunome Inc is a biotechnology company focused on discovering and developing novel immunotherapies for treating cancers and infectious diseases. Founded in [year], Immunome has already achieved significant milestones in its journey. The company's team of scientists and researchers utilize cutting-edge technologies to identify and isolate highly effective antibodies that can specifically target disease-causing agents. Immunome's groundbreaking work has garnered recognition in the scientific community and has attracted collaborations with leading pharmaceutical companies. With a vision to revolutionize the field of immunotherapy, Immunome Inc continues to advance its pipeline of potential treatments, offering hope for patients worldwide.
Immunome Inc. has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in October 2020, raising $26 million. In January 2021, Immunome entered into a collaboration agreement with AbCellera to discover and develop antibodies for infectious diseases. This collaboration aims to leverage Immunome's proprietary discovery engine, IMM-BCP, to select and optimize therapeutic candidates. In addition, Immunome has received funding from various sources, including the National Institutes of Health (NIH), to support the development of its pipeline and advance its immunotherapy programs. These milestones demonstrate Immunome Inc.'s progress and commitment to advancing innovative solutions in the field of immunology.
Immunome Inc is primarily present in the United States.
Immunome Inc represents a strong commitment to innovation, cutting-edge research, and the development of novel immunotherapies. The company's corporate philosophy revolves around harnessing the power of the immune system to target and treat diseases, with a particular focus on cancer and infectious diseases. With a team of highly skilled scientists and industry experts, Immunome Inc is dedicated to discovering and advancing breakthrough therapies that can make a meaningful impact in patients' lives. By combining deep knowledge of the immune system with advanced technologies, Immunome Inc strives to deliver transformative treatments to address unmet medical needs.
Analyytikot asettavat tällä hetkellä Immunome-osakkeelle keskimääräisen tavoitehinnan 35,25 USD (mediaani: 35,50 USD), mikä merkitsee +93,3 % viimeisimpään hintaan verrattuna. Konsensus perustuu 22 analyytikkoarvioon.
22 analyytikkoa arvioi tällä hetkellä Immunome-osaketta: 20 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Immunome-yhtiöltä 307 692,00 USD liikevaihtoa ja −2,90 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Immunome-osake noteerataan hintaan 16,24 EUR (18,24 USD).
Immunome-osake (IMNM) on listattuna 1 pörssissä, muun muassa: NASDAQ (IMNM).
Immunome Inc is an innovative biotechnology company specializing in the development of biopharmaceuticals for the treatment of autoimmune diseases and cancer. The company uses its proprietary platform technologies to identify antibodies that specifically bind to target molecules. These antibodies can then be used as therapeutics or biomarkers for disease diagnosis. The company has two main business areas: 1. Research and development of biopharmaceuticals: The company uses its proprietary sequencing and data analytics platform to identify unique antibodies that selectively target disease targets. Immunome has already developed several antibody candidates that are being tested in clinical trials for the treatment of autoimmune diseases and cancer. 2. Diagnostics: Immunome also offers diagnostic solutions based on its proprietary technologies. The company provides molecular diagnostic tests for identifying pathogens in blood and other bodily fluids. These tests enable faster and more accurate diagnosis of infectious diseases and can help detect and combat outbreaks of infectious diseases early on. Immunome aims to offer its customers high-quality products and solutions based on the latest scientific knowledge and technologies. The company invests heavily in research and development to further improve its technologies and products and to find new applications. Some of Immunome's key products include: 1. IMM-01: A novel antibody candidate targeting a target molecule that is overexpressed in autoimmune diseases such as rheumatoid arthritis and lupus. IMM-01 is currently in clinical trials and shows promising results in improving symptoms of autoimmune diseases. 2. IMM-101: An antibody candidate targeting a target molecule expressed in certain types of cancer such as pancreatic cancer and breast cancer. IMM-101 is currently being tested in clinical trials and could be a promising new therapy for cancer patients. 3. Molecular diagnostic tests: Immunome offers a range of molecular diagnostic tests, including tests for identifying bacteria and viruses that cause infectious diseases such as Lyme borreliosis and respiratory infections. Overall, Immunome has a promising business model based on its proprietary technology platform and its focus on developing a new generation of biopharmaceuticals and diagnostic solutions. The company has already developed promising products and is on a strong growth trajectory. By continuously investing in research and development and expanding its product line, Immunome will continue to play a leading role in the biotechnology industry.
odotettu liikevaihto Immunome on 307 692,00 USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Immunome on −252,89 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Immunome:n hinta-voitto-suhde (P/E) on tällä hetkellä −6,30. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Immunome-osakkeen arvostusta.
Immunome:n hinta-myynti-suhde (P/S) on tällä hetkellä 5 178,17. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Immunome-osakkeen arvostuskennuslukuna.
Immunome:n Eulpool-laatuscore on 2/10.
Immunome:n ISIN on US45257U1088. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Immunome:n WKN on A2QD9D. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Immunome:n ticker on IMNM. Tämä pörssinoteeraus käytetään Immunome-osakkeiden kauppaan pörssissä.
Immunome osake
Immunome vertaisryhmä
Immunome Ticker
Immunome FIGI
Kaikki tunnusluvut ja syvällinen analyysi Immunome:sta
Meidän osakeanalyysimme Immunome-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Immunome:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: